GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Shanghai Pharmaceuticals Holding Co Ltd (OTCPK:SHPMY) » Definitions » Research & Development

SHPMY (Shanghai Pharmaceuticals Holding Co) Research & Development : $332 Mil (TTM As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Shanghai Pharmaceuticals Holding Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Shanghai Pharmaceuticals Holding Co's Research & Development for the three months ended in Dec. 2024 was $107 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $332 Mil.

Shanghai Pharmaceuticals Holding Co Research & Development Historical Data

The historical data trend for Shanghai Pharmaceuticals Holding Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Pharmaceuticals Holding Co Research & Development Chart

Shanghai Pharmaceuticals Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 253.34 312.01 302.97 308.68 328.87

Shanghai Pharmaceuticals Holding Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.08 69.63 83.20 72.23 106.90

Shanghai Pharmaceuticals Holding Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $332 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Pharmaceuticals Holding Co  (OTCPK:SHPMY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shanghai Pharmaceuticals Holding Co Research & Development Related Terms

Thank you for viewing the detailed overview of Shanghai Pharmaceuticals Holding Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Pharmaceuticals Holding Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Shanghai Pharmaceuticals Holding Co Ltd (OTCPK:SHPMY) » Definitions » Research & Development
Comparable Companies
SHSE:600332 SHSE:600998 SHSE:600511 SHSE:600739 SHSE:600056 SZSE:000028 SZSE:301015 SZSE:000950 SHSE:603368 SZSE:002589 MCK COR CAH ASX:SIG HSIC HKSE:01099 MIL:AMP XSWX:GALE NZSE:EBO TSE:7459
Traded in Other Exchanges
SHPMF:USA 02607:Hong Kong S1R:Germany 601607:China
Address
No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Website
https://www.sphchina.com
Shanghai Pharmaceuticals is the second-largest medical distributor in China by revenue. It is vertically integrated and provides healthcare services in research and development, manufacturing, distribution, and retail. As of 2023, medical distribution is the largest segment, accounting for 89.8% of total revenue. It also has coverage of 31 provinces and cities nationwide.